Janux Therapeutics(JANX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights SAN DIEGO, May 7, 2024 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2024 and provided a business ...